Lead on Purpose

SEPTEMBER 8, 2009

Over 150 companies, including Durkee, Cremora, San Giorgio, Ronzoni, and McCormick, now use the entire line of Flapper products, and Weatherchem continues to lead the industry in offering the widest, most innovative array of closure products. Unfortunately, my gesture was rebuffed and the union decided to strike.

Committee 140

Committee Automotive Ethics Productivity 140

Strategy Driven

JULY 13, 2011

While you can find numerous books focused on the topic of corporate finance, few offer the type of information managers need to help them make important decisions day in and day out. Examines ways to maintain and grow value through mergers, acquisitions, and portfolio management.

ROIC 62

ROIC Balanced Scorecard Metrics McKinsey 62

Harvard Business Review

SEPTEMBER 21, 2018

Corporate directors and executives alike recognize that today’s pace of change continues to accelerate and that firms need to innovate to stay ahead. But are boards doing enough to support innovation, as they should? We found that, overall, innovation does not rank as a top strategic challenge for the majority of boards.

Innovation 10

Innovation Short-term Telecommunications Long-term 10

Strategy Driven

DECEMBER 13, 2018

A few years back, I coached a national pharmaceutical team with distinct geographies. Strong Identity is a by-product of being able to relate to and feel good about the team, what it stands for, and the success it creates, as well as the relationships and camaraderie experienced by its members. It takes effort, energy and time.

Team 59

Team Pharmaceuticals Project Learning-by-Doing 59

Harvard Business Review

SEPTEMBER 23, 2014

I often hear this question when I visit companies and speak about how to make an innovative idea less terrifying to high level executives. There are plenty of pundits arguing that big companies need to innovate, and pointing out that it is difficult to do so. And yet management sponsorship is crucial for any ambitious initiative.

Innovation 11

Innovation P&L Short-term Company 11

Coaching Tip

MARCH 15, 2011

In a capitalist democracy, government should not be involved with what we in the private sector do, which is managing time to manage money. All it takes is the desire to be innovative and creative in tackling a problem. Entrepreneurship. You needn’t work for yourself – or even be working at all – to be an entrepreneur.

Pharmaceuticals 84

Pharmaceuticals Creativity Long-term Power 84

Harvard Business Review

DECEMBER 23, 2016

When partners in an alliance come into conflict, it can be just what is needed to produce a technically and commercially successful product. Heat degrades the substrate of innovation, while light catalyzes it.” ” This idea that disagreement and conflict between groups can be productive is not new.

Productivity 8

Productivity Products Survey Strategic Fit 8

Harvard Business Review

DECEMBER 27, 2016

A simple question was asked: are hospitals ranked more highly when they are led by medically trained doctors or non-MD professional managers? The analysis showed that hospital quality scores are approximately 25% higher in physician-run hospitals than in manager-run hospitals. …and how training can make them even better ones.

Management 15

Management 360-Degree Feedback Mayo Training 15

Harvard Business Review

JANUARY 27, 2016

Much fanfare has been paid to the term “disruptive innovation” over the past few years. Disruptive innovations are: Cheaper (from a customer perspective). Because disruptive products were cheaper, more accessible, and built on new technology architectures, they tended to be crummier than the existing highest-end solutions.

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

OCTOBER 29, 2012

If the cost of innovation is falling, that should enable more of it from poorer countries, companies or cooperatives. If it's not, the already big and already rich will dominate innovation. Some of this may just be the product of the high regulatory costs in pharmaceuticals, but research by Harvard's F.M.

Cost 8

Cost Innovation Wireless Disruptive Innovation 8

Harvard Business Review

DECEMBER 20, 2011

The two biggest product stories of 2011 were arguably Lipitor and the iPhone 4S. The Lipitor story seems to be about a managed end: the highly anticipated demise (due to the expiration of its patent last Nov. Apple use life-cycle management to explore a new way to drive the business and business model forward. Both Pfizer and.

Disintermediation 15

Disintermediation Industry Pharmaceuticals Price 15

Harvard Business Review

JUNE 29, 2015

And a recent working paper out of the Dusseldorf Institute for Competition Economics ( DICE ), a think tank of sorts, focuses on the latter by exploring whether leveraged buyouts (LBOs) make firms more innovative. PE investors don’t typically invest in firms known for innovation. ” There were other limitations.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

SEPTEMBER 5, 2013

With scarcely any help from management, knowledge workers can increase their productivity by 20%. Yet here is the challenge you face as a senior executive: You cannot manage your knowledge workers in the traditional and intrusive way you might have done with manual workers.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

JUNE 9, 2017

Few issues are more foundational to driving improvements in human health than creating productive, progressive relationships between clinical medicine and the biopharmaceutical industry. During our careers, we have worked in industry, academia, clinical medicine, and government and have managed successful academia-industry collaborations.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

FEBRUARY 21, 2012

Having a strong domestic manufacturing base is vital to the United States maintaining its world leadership in innovation. Making parts for an iPhone is a challenging mix of materials science, mechanical engineering, precision fabrication, and managing mind-boggling complexity in the supply chain.

Supply Chain 15

Supply Chain Offshoring Engineering Pharmaceuticals 15

Harvard Business Review

FEBRUARY 29, 2016

We then tested the model using quantitative data about the incidence of safety-related errors in the context of pharmaceutical drugs. The occurrence of a serious error — such as a shuttle explosion, a large-scale oil spill, or a safety-related product recall — triggers the learning cycle. New executives take the helm.

Organization 8

Organization McCombs Pharmaceuticals Learning-by-Doing 8

Harvard Business Review

AUGUST 14, 2018

Many leading American digital firms, including Google, Amazon, eBay, and Uber, have successfully expanded internationally by introducing their products, services, and platforms in other countries. poor management of relations with Chinese regulators and the government. ineffective innovation strategies. market on China.

Competitive Advantage 11

Competitive Advantage Business Model Technology Marketing 11

Harvard Business Review

OCTOBER 7, 2014

Otherwise, strategy often becomes a diffuse product of group thinking and compromises among multiple stakeholders in the organization. That’s why it is essential for the CEO to cut through the corporate clutter and reach out to the colleagues who are closest to the customers: the frontline sales people and their direct managers.

CEO 11

CEO Strategy Pharmaceuticals B2B 11

Strategy Driven

MARCH 18, 2011

PL and CM: Coherent companies – those that possess a capabilities system that aligns their strategy with their product/service portfolio – generate superior performance over time, which is what we call the coherence premium. SD : What is the ‘coherence premium?’. SD : What does it mean to have a ‘right to win?’.

Resources 53

Resources Industry System Strategy 53

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MAY 26, 2016

That is good news for managers and investors. While a dynamic, competitive economy rewards innovative firms with high profits and punishes poor performers with low profits, sustained aggregate profits suggest, instead, that firms are able to get away with higher prices because competition is limited. Profits are up.

Pharmaceuticals 11

Pharmaceuticals Politics Price Chemicals 11

Harvard Business Review

SEPTEMBER 13, 2012

Managers and business analysts will often be called upon to conduct data-driven experiments, to interpret data, and to create innovative data-based products and services. Adept at mathematical reasoning : How many of your managers today are really "numerate" — competent in the interpretation and use of numeric data?

Skills 17

Skills Pharmaceuticals Sample Business Intelligence 17

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

JUNE 16, 2011

So it is with most breakthrough innovations and banner financial years. Investors grapple daily in an effort to figure out how to value companies whose accounting assets — things like land, capital, products, and licenses — don't adequately express their true market value. If you can't measure it, how can you manage it?

Intangible Assets 15

Intangible Assets Analysis Pharmaceuticals Innovation 15

Harvard Business Review

DECEMBER 14, 2017

To be the change that many desire, these new mergers and acquisitions, and the others that will likely follow, must produce a higher-quality product for consumers (and satisfy physicians and other health professionals) at an affordable price. It depends above all on the results.

Health Care 8

Health Care System Insurance Pharmaceuticals 8

Harvard Business Review

OCTOBER 25, 2018

We focus on economic profit rather than revenue size, market share, or productivity growth because these other metrics risk including firms that are simply large and may not create economic value. Productivity can help; but it is not enough to achieve superstardom.

Industry 13

Industry Company GDP Bottom-up 13

Harvard Business Review

MARCH 1, 2011

Editor's note: This post is part of a three-week series examining innovation in health care, published in partnership with the Advanced Leadership Initiative at Harvard University. And that's true in many areas: New devices, pharmaceuticals, and surgical techniques regularly get developed and incorporated into practice.

Health Care 15

Health Care Biotechnology Mayo Pharmaceuticals 15

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Risk and outcomes, as the scenario plays out, will be managed by predictive models, which are powered by machine learning algorithms that will improve their accuracy rates over time.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

OCTOBER 13, 2011

Risk management processes don't — but they should. The pharmaceutical industry also creates products with complex interactions and potentially dangerous side effects. Banks can simulate the pharmaceutical approach, and learn much about consumer behavior and its evolution — without putting customers at risk.

Banking 10

Banking Pharmaceuticals Microfinance Risk Management 10

Harvard Business Review

MAY 29, 2013

SAP, the German software giant, announced that it hopes to hire hundreds of autistics as talented programmers and product testers. SAP''s Bangalore office saw its productivity increase after deploying autistic hires. Ethics Human resources Innovation OCPD' I don''t know.

Competitive Advantage 9

Competitive Advantage Ethics Human Resources Pharmaceuticals 9

Harvard Business Review

JANUARY 31, 2013

Second, we see a raft of innovations that will alter how products are designed, manufactured and sold — everything from nanotechnologies to 3D printing. Then, manufacturing's most important role is as a driver of innovation, trade, and productivity. Innovations Are Changing The Way We Design Products.

Globalization 9

Globalization Supply Chain Pharmaceuticals McKinsey 9

Harvard Business Review

FEBRUARY 17, 2011

Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). In effect, the VCs at Nadathur Holdings serve as the executive team for a miniature healthcare innovation ecosystem.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it''s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. Companies should consider offering rewards for people who solve internal problems or create new products.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it’s a wonder we have any innovative products at all. Effective means of boosting innovation already exist, but not enough companies are making use of them. It’s like that. It doesn’t have to be this way. You can see why: For decades in the U.S.,

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 5, 2016

Pearson, the educational publisher, measures the efficacy of its products to improve educational outcomes. Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. There is enough time to develop innovative solutions to achieve the results.

Incentives 8

Incentives Health Care Education Insurance 8